Today The Novartis AG (NVS) Rating Reiterated by J P Morgan Chase & Co

Today The Novartis AG (NVS) Rating Reiterated by J P Morgan Chase & Co

J P Morgan Chase & Co reaffirmed their neutral rating on shares of Novartis AG (NYSE:NVS) in a research note published on Thursday morning.

A number of other research firms also recently weighed in on NVS. Jefferies Group LLC reiterated a buy rating on shares of Novartis AG in a research report on Sunday, October 16th. TheStreet downgraded Novartis AG from a buy rating to a hold rating in a research report on Wednesday, September 28th. Zacks Investment Research downgraded Novartis AG from a hold rating to a sell rating in a research report on Wednesday, September 21st. Berenberg Bank downgraded Novartis AG from a buy rating to a hold rating in a research report on Tuesday, January 17th. Finally, Credit Suisse Group downgraded Novartis AG from an outperform rating to a neutral rating in a research report on Wednesday, January 11th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of Hold and an average target price of $85.18.

Shares of Novartis AG (NYSE:NVS) traded up 1.2051% during mid-day trading on Thursday, reaching $70.8739. The company had a trading volume of 820,074 shares. The company has a market cap of $168.36 billion, a price-to-earnings ratio of 24.9908 and a beta of 0.68. Novartis AG has a 52-week low of $66.93 and a 52-week high of $83.58. The firm’s 50-day moving average price is $71.56 and its 200 day moving average price is $76.20.

Novartis AG (NYSE:NVS) last released its earnings results on Wednesday, January 25th. The company reported $1.12 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.12. The firm earned $12.32 billion during the quarter, compared to the consensus estimate of $12.34 billion. Novartis AG had a return on equity of 15.25% and a net margin of 13.98%. The company’s revenue was down 1.6% compared to the same quarter last year. During the same period in the prior year, the company posted $1.14 EPS. Equities analysts expect that Novartis AG will post $4.71 EPS for the current year.

A number of institutional investors have recently modified their holdings of the company. The Manufacturers Life Insurance Company bought a new stake in shares of Novartis AG during the third quarter valued at $304,776,000. CGOV Asset Management bought a new stake in shares of Novartis AG during the third quarter valued at $82,650,000. Parnassus Investments CA boosted its stake in shares of Novartis AG by 22.9% in the third quarter. Parnassus Investments CA now owns 4,278,005 shares of the company’s stock valued at $337,791,000 after buying an additional 796,109 shares during the last quarter. Aristotle Capital Management LLC boosted its stake in shares of Novartis AG by 31.9% in the second quarter. Aristotle Capital Management LLC now owns 2,736,946 shares of the company’s stock valued at $225,825,000 after buying an additional 662,285 shares during the last quarter. Finally, FMR LLC boosted its stake in shares of Novartis AG by 65.6% in the second quarter. FMR LLC now owns 1,208,384 shares of the company’s stock valued at $99,704,000 after buying an additional 478,679 shares during the last quarter. 9.84% of the stock is owned by institutional investors and hedge funds.

Novartis AG Company Profile

Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.

Related posts

Leave a Comment